Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking too much semaglutide, or escalating doses faster than your body can adapt, tends to amplify the medicine's known side effects rather than produce entirely new ones. The NHS semaglutide medicines page documents a GI-led profile — nausea, vomiting, diarrhoea, constipation — that is well-characterised from clinical trials. What changes when the dose outpaces tolerance is the intensity and duration of those effects, not the list itself. Semaglutide is a prescription-only medicine; the dose you take and any changes to it are decisions made by a prescriber, not adjustments you should make independently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial (published in the New England Journal of Medicine and the foundational evidence base for Wegovy's licence) ran 68 weeks in adults with obesity. Gastrointestinal events were the most common adverse effects at every dose level, and they were clearly more frequent during titration periods than at stable maintenance doses. That pattern matters. It tells us that the body does adapt, but that the adaptation takes time, and that compressing that time, or skipping titration steps, is where most of the avoidable discomfort originates.
The NHS medicines information for semaglutide describes the typical experience: nausea and vomiting usually peak in the days following a dose increase, then ease. For most people, symptoms settle within one to two weeks. If they don't, or if they are severe enough to prevent eating or drinking, that is a signal to speak to your prescriber rather than push through.
If you want a fuller picture before starting, you can read about what to expect from Ozempic and semaglutide side effects on a dedicated page. The medicine's mechanism (slowing gastric emptying, reducing appetite, acting on gut receptors) becomes overwhelming when the dose exceeds what the digestive system can accommodate. Worth knowing.
Most nausea on semaglutide is unpleasant but not dangerous. A smaller number of symptoms are different in kind, not just in degree, and warrant urgent assessment.
On 29 January 2026, the MHRA issued a formal Drug Safety Update for GLP-1 receptor agonists, including semaglutide, specifically highlighting acute pancreatitis as a known but infrequent serious risk. The symptom to act on: severe stomach pain that doesn't pass, particularly pain that radiates into the back, with or without vomiting. Seek emergency medical help. Do not wait to see if it settles. Gallbladder problems (including gallstones and inflammation) are also associated with significant weight loss and with GLP-1 medicines specifically; upper-right abdominal pain, especially after eating, should be assessed.
Prolonged or severe vomiting and diarrhoea carry a secondary risk: dehydration serious enough to impair kidney function. This is not theoretical. If you cannot keep fluids down for more than a day, that is a clinical situation. Other signs to take seriously include an allergic reaction (swelling of the face or throat, difficulty breathing), sudden changes in vision, and any new or worsening thoughts about self-harm, all documented in the summary of product characteristics on the eMC. The full list of serious symptoms is there, and it is worth reading before you start treatment.
If you are in any doubt, call 111 or go to A&E. Time matters with pancreatitis.
The question our prescribers hear regularly is whether eating too much on Wegovy makes you feel worse. The short answer is yes: semaglutide slows how fast food leaves the stomach, so large meals, high-fat meals or eating quickly can trigger or worsen nausea, reflux and vomiting even at a stable dose. This is not strictly a dose problem, it is the medicine doing what it is designed to do against eating patterns it was not designed for.
Similarly, specific foods and portion sizes interact with Wegovy's gastric-emptying effect in ways that amplify side effects without any change to the dose itself. Smaller meals, slower eating, lower fat content and adequate hydration are the practical levers. They are not magic, but they are consistently useful.
What they are not is a substitute for speaking to a prescriber if symptoms are severe or prolonged. If your current dose is producing side effects that are genuinely affecting daily life, the prescriber's options include pausing titration, returning to a previous dose, or reviewing whether the medicine is still the right fit. At nume, a real clinician reads your consultation (not software) and that same clinical oversight continues at every repeat order. The prescriber can act on what you tell them.
You can explore the broader Wegovy side-effect picture, or look at more serious semaglutide side effects covered in depth on separate pages. The Wegovy treatment page sets out how the medicine works and what the licensed schedule involves.
If you have questions about whether semaglutide suits your health history, our prescribers discuss exactly that as part of the free consultation. Speak to our prescribers, suitability, dose, and any concerns you have are all part of what they assess.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.